Agenus Inc. · NASDAQ:AGEN

Agenus — SITC 37th Annual Meeting 2022

18 slides from Agenus's conference presentation, Nov 12, 2022

  1. Slide 1: SITC 2022 37th Annual Meeting

    Slide 1: SITC 2022 37th Annual Meeting

    2022 NOVEMBER 8-12 MASSACHUSETTS The Society for immunotherapy of Cancer 37" Annual Meeting and Pre-Conterence Programs: = - THE LEADING CANCER IMMUNOTHERAPY AND TUMOR IMMUNOLOGY CONFERENCE mete! a

  2. Slide 2: Botensilimab with balstilimab in cold and I-O refractory metastatic solid tumors

    Slide 2: Botensilimab with balstilimab in cold and I-O refractory metastatic solid tumors

    Botensilimab, a novel innate/adaptive immune activator with balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors Presented by: Breelyn A. Wilky, MD University of Colorado Cancer Center Director of Sarcoma Medical Oncology Deputy Associate Director for Clinical Research Aurora

  3. Slide 3: Disclosures

    Slide 3: Disclosures

    Disclosures Consultant/Advisory Role: Adaptimmune, Adcendo, Daiichi Sankyo, Deciphera, Epizyme, Polaris, Springworks Institutional Coordinating PI: Agenus

  4. Slide 4: Background: Advanced Cancer Population

    Slide 4: Background: Advanced Cancer Population

    Background 100% ADVANCED CANCER POPULATION I-O BENEFIT 40% I-O ELIGIBLE FIRST I-O REVOLUTION: PD-(L)1 ± CTLA-4 • Paradigm shift: curative potential • Majority do not benefit from I-O treatment 0% LAST DECADE 2022 Agenus projections based on Haslam & Prasad, JAMA 2019 and Evaluate Pharma 2022 global

  5. Slide 5: Background: Advanced Cancer Population

    Slide 5: Background: Advanced Cancer Population

    Background 100% 60% NO I-O OPTION ADVANCED CANCER POPULATION I-O BENEFIT NEXT I-O REVOLUTION... • Significant unmet need • Majority are “cold” 40% • New I-O urgently needed I-O ELIGIBLE FIRST I-O REVOLUTION: PD-(L)1 ± CTLA-4 • Paradigm shift: curative potential • Majority do not benefit from I-O tre

  6. Slide 6: Novel Immunotherapy Agents

    Slide 6: Novel Immunotherapy Agents

    Novel Immunotherapy Agents botensilimab balstilimab Fc-enhanced CTLA-4 Inhibitor PD-1 Inhibitor Active in cold and I-O refractory tumors1 Safety and efficacy analogous to approved anti-PD-1 mAbs4,5 • ↑ T cell priming, expansion, memory2,3 • >750 patients treated; 10 ongoing trials / 2 completed • ↑

  7. Slide 7: C-800-01 Study

    Slide 7: C-800-01 Study

    C-800-01 Study NCT03860272: First-in-human trial of botensilimab (bot) ± balstilimab (bal) in patients with advanced cancer1,2 POPULATION DESIGN Key Eligibility bot Monotherapy every 3 weeks • Refractory to standard treatment [Fc-enhanced CTLA-4] • Prior I-O therapy allowed 0.1, 0.3, 1, 2, 3 mg/kg Q

  8. Slide 8: C-800-01 Analysis Population

    Slide 8: C-800-01 Analysis Population

    C-800-01 Analysis Population NCT03860272: First-in-human trial of botensilimab (bot) ± balstilimab (bal) in patients with advanced cancer1,2 POPULATION DESIGN Evaluable Combination Patients 125 treated with 1 or 2 mg/kg bot + bal* as of bot + bal Combination therapy 19 May 2022 with ≥1 Q6W imaging a

  9. Slide 9: Patient Characteristics (N=125)

    Slide 9: Patient Characteristics (N=125)

    Patient Characteristics (N=125) ALL PATIENTS ALL PATIENTS Age, median (range) 59 (25-83) Select expansion cohorts, n (%) Sex, n (%) MSS CRC 59 (47) Male 48 (38) Recurrent Platinum Resistant/Refractory Ovarian 19 (15) Female 77 (62) Sarcoma 12 (10) ECOG PS at baseline, n (%) 0 56 (45) Anti-PD-(L)1 R/

  10. Slide 10: Efficacy in Combination Patients (N=125)

    Slide 10: Efficacy in Combination Patients (N=125)

    Efficacy in Combination Patients (N=125) 1300 1200 1100 1000 900 800 Best Percent Change 700 ALL PATIENTS From Baseline (%) 600 500 400 300 200 20% Tumor ORR, %* 20% (95% CI, 13-28%) 100 Growth 00 -100 -200 BOR, n (%) -300 30% Tumor -400 -500 Reduction CR 3 (2) -600 -700 -800 -900 PR 22 (18) -1000 -

  11. Slide 11: Safety (N=125)

    Slide 11: Safety (N=125)

    Safety (N=125) All TRAEs of Any Grade in ≥10% of All Patients n (%) ALL GRADE GRADE 3 GRADE 4 ANY TRAE 111 (89) 40 (32) 3 (2) GASTROINTESTINAL Immune-mediated diarrhea/colitis* 48 (38) 23 (18) 1 (1) Other diarrhea 16 (13) 0 0 Nausea 32 (26) 1 (1) 0 Vomiting 17 (14) 0 0 CONSTITUTIONAL Fatigue 37 (30)

  12. Slide 12: MSS CRC Efficacy (n=59)

    Slide 12: MSS CRC Efficacy (n=59)

    MSS CRC Efficacy (n=59) 100 90 80 70 60 EFFICACY Best Percent Change 50 From Baseline (%) 40 30 ORR, %* 22% (95% CI, 12-35%) 20 ∞ 20% Tumor 10 + 0 Growth BOR, n (%) -10 +§ -20 -30 + 30% Tumor CR 1 (2) -40 + Reduction -50 -60 + + + + PR 12 (20) -70 + -80 -90 SD 30 (51) + -100 -110 PD 16 (27) 0 6 12 1

  13. Slide 13: Recurrent Platinum Refractory/Resistant Ovarian Efficacy (n=19)

    Slide 13: Recurrent Platinum Refractory/Resistant Ovarian Efficacy (n=19)

    Recurrent Platinum Refractory/Resistant Ovarian Efficacy (n=19) 130 120 110 EFFICACY 100 Histology 90 80 High grade serous Best Percent Change 70 ORR, %* 26% (95% CI, 9-51%) From Baseline (%) 60 Clear cell 50 40 Carcinosarcoma 30 20 20% Tumor BOR, n (%) 10 Endometrioid/clear cell 0 Growth -10 -20 CR

  14. Slide 14: Sarcoma Efficacy (n=12)

    Slide 14: Sarcoma Efficacy (n=12)

    Sarcoma Efficacy (n=12) 130 120 110 100 Subtype 90 EFFICACY 80 Cutaneous Angiosarcoma 70 Best Percent Change From Baseline (%) 60 Leiomyosarcoma 50 40 Liposarcoma ORR, %* 42% (95% CI, 15-72%) 30 Pleomorphic 20 20% Tumor 10 0 Visceral Angiosarcoma Growth BOR, n (%) -10 -20 -30 30% Tumor CR 1 (8) -40

  15. Slide 15: Anti-PD-(L)1 R/R NSCLC Efficacy (n=4)

    Slide 15: Anti-PD-(L)1 R/R NSCLC Efficacy (n=4)

    Anti-PD-(L)1 R/R NSCLC Efficacy (n=4) 110 100 90 80 70 EFFICACY 60 Best Percent Change From Baseline (%) 50 40 30 ORR, % 50% (95% CI, 7-93%) 20 20% Tumor 10 0 Growth BOR, n (%) -10 -20 -30 30% Tumor CR 0 (0) -40 Reduction -50 -60 + PR 2 (50) -70 -80 -90 SD 1 (25) 0 6 12 18 24 30 36 42 48 54 60 66 We

  16. Slide 16: Summary & Future Directions

    Slide 16: Summary & Future Directions

    Summary & Future Directions • Botensilimab plus balstilimab demonstrates durable responses across a broad range of heavily pretreated unselected patients with cold and/or I-O relapsed/refractory tumors • Results presented today in MSS CRC, ovarian, sarcoma (including angiosarcoma and liposarcoma), a

  17. Slide 17: Acknowledgements

    Slide 17: Acknowledgements

    Acknowledgements Agenus Inc. funded and is the sponsor of this study. • The authors would like to thank the patients and their families for participating in the C-800-01 study, as well as the trial coordinators and investigators for their contributions.

  18. Slide 18: Abbreviations

    Slide 18: Abbreviations

    Abbreviations AE, adverse event ALT, alanine aminotransferase mAb, monoclonal antibody APC, antigen presenting cell Mets, metastases AST, aspartate aminotransferase MSI, microsatellite instability bal, balstilimab MSS, microsatellite stable BOR, best overall response NK, natural killer bot, botensil

Source: Internet Archive copy of agenusbio.com

More decks from Agenus Inc.

All 34 Agenus decks